Hand rejuvenation can mean several different things: restoring lost volume, treating brown spots or improving dry, creased skin. These concerns can appear together, but they do not have the same treatment. A hand filler is intended to restore fullness on the back of the hand; its effect should be judged against that goal.
The most useful evidence comes from studies performed on hands with the exact product being considered. A result reported for a cheek, jawline or décolleté does not establish what will happen in a hand.
Volume, spots and texture: identify the concern first
With less fullness, tendons and veins may become more noticeable. Restoring volume can soften that appearance, but it does not remove the veins themselves. Brown spots and rough patches require a separate skin assessment; a rough or changing area should be examined before it is treated as a cosmetic concern. The American Academy of Dermatology’s hand guide distinguishes these different changes.
Daily sun protection and moisturizer support skin care. They do not replace volume that has been lost. Equally, a volume-filler study is not evidence that the product removes pigmentation or treats every type of loose skin.
What have hand-filler studies actually measured?
Two U.S. regulatory studies evaluated specific products: Radiesse, containing calcium hydroxylapatite, and Restylane Lyft with Lidocaine, a hyaluronic acid gel. Both used the Merz Hand Grading Scale to assess the appearance of volume loss. A response meant an improvement of at least one grade, not a return to a particular age or a percentage increase in collagen.
These were separate studies, not a direct comparison between the products. Their response percentages cannot establish which filler is better for you.
| Study | How it was assessed | Primary result |
|---|---|---|
| Radiesse: 114 people assigned to immediate or delayed treatment | A blinded evaluator assessed improvement in both hands at three months | 64 of 85 treated participants (75.3%) responded, compared with 1 of 29 controls (3.4%) |
| Restylane Lyft with Lidocaine: 85 people in the main effectiveness analysis | One hand was treated and the other served as a control; assessment at 12 weeks | 85.9% of treated hands responded, compared with 21.2% of untreated hands |
Sources: FDA Radiesse hand study, Table 16 and FDA Restylane Lyft hand study, Table 10. These documents describe U.S. evidence and indications; they do not establish authorization in Mexico or the availability of a particular product at a clinic.
How long can a result last?
The follow-up period matters, as does whether people received another treatment. In the Restylane Lyft study, 75.9% of treated hands still met the improvement threshold at 24 weeks, versus 30.1% of control hands, among 83 participants assessed at that visit. An optional four-week touch-up was part of the study, and 74 of the 89 participants in its safety population received it. These results should not be described as the effect of one injection visit for everyone. FDA study, Tables 2 and 11.
The Radiesse study followed participants for up to 12 months and allowed repeat treatment from six months. Its 12-month result after the initial treatment was based on only 22 participants; repeat-treatment results were reported separately. That is a reason to ask how a duration claim was calculated, rather than treating “one year” as a promise. FDA study, Table 20.
Recovery includes how your hands function
Bruising, swelling, tenderness and pain can follow treatment. Some reactions last longer than two weeks, and lumps or delayed reactions can occur. The Radiesse hand instructions report temporary difficulty with activities in the pivotal study. Recovery planning should account for work, exercise and other tasks that rely on your hands.
The current Restylane Lyft instructions also include a specific functional warning. During its six-month needle-injection study, a reduction of at least 10 degrees in thumb bending was recorded in 22 of 89 participants; some episodes were unresolved at the last recorded assessment. Ten of those 22 also showed a reduction in the untreated hand. These measurements do not establish that filler caused every change or how each change evolved beyond follow-up.
Both product instructions warn about injection into a blood vessel or tendon. Unusual pain or pale skin during or shortly after an injection needs prompt medical attention. These are medical procedures requiring a practitioner who knows hand anatomy and can recognize and manage complications.
Questions that make a consultation more useful
- Is the main concern volume loss, pigmentation, texture or a combination?
- Which exact product is being proposed, and what hand-specific evidence supports it?
- Does the expected result include a touch-up or later repeat treatment?
- What changes in hand use should I plan for, and who will assess a concern afterward?
- How do my medical history, allergies, medicines and any previous hand procedures affect suitability?
For the broader differences between injectable materials, see our guides to dermal fillers and Radiesse versus Sculptra. For hydration and surface-quality goals, the skinboosters guide addresses a different treatment question.